Compile Data Set for Download or QSAR
maximum 50k data

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB (change energy unit to kcal/mol)

Found 14 hits in this display   

TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  6.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  6.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1 [179-426](Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  6.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  6.80E+3nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  6.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  3.75E+4nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  3.75E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  3.75E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  3.75E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataIC50:  3.75E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataEC50:  7.70E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataEC50:  7.70E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 1(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataEC50:  7.70E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 ceils per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor A(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US11426393, Compound Table XV.7 | US8598210, Table...)
Affinity DataEC50:  7.70E+3nMMore data for this Ligand-Target Pair
In DepthDetails US Patent